Evommune (EVMN) Cash & Current Investments (2024 - 2026)

Evommune (EVMN) has reported Cash & Current Investments for 3 consecutive years, with $211.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments rose 3607.29% year-over-year to $211.5 million; the TTM figure through Mar 2026 stood at $211.5 million (up 3607.29% YoY), while the FY2025 annual figure was $149.2 million, up 107.11% from the prior year.
• Cash & Current Investments grew to $211.5 million in Q1 2026 per EVMN's latest filing, from $149.2 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $211.5 million in Q1 2026 and bottomed at $5.7 million in Q1 2025.
• Historically, Cash & Current Investments has averaged $88.8 million across 3 years, with a median of $74.1 million in 2024.
• Annual changes were most pronounced in 2025 — Cash & Current Investments soared 107.11% — and 2026, when it surged 3607.29%.
• Evommune's Cash & Current Investments stood at $72.0 million in 2024, then jumped by 107.11% to $149.2 million in 2025, then surged by 41.73% to $211.5 million in 2026.
• Business Quant data shows EVMN's Cash & Current Investments at $211.5 million in Q1 2026, $149.2 million in Q4 2025, and $76.1 million in Q3 2025.